Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
International Journal of Clinical Oncology
Published in: International Journal of Clinical Oncology 4/2005

01-08-2005 | ORIGINAL ARTICLE

Feasibility of chemoradiation therapy with protracted infusion of5-fluorouracil for esophageal cancer patients not suitable for cisplatin

Authors: Bryan H. Burmeister, Euan T. Walpole, Elizabeth A. Burmeister, Janine Thomas, Damien B. Thomson, Jennifer A. Harvey, B. Mark Smithers, David C. Gotley

Published in: International Journal of Clinical Oncology | Issue 4/2005

Login to get access
Metadata
Title
Feasibility of chemoradiation therapy with protracted infusion of5-fluorouracil for esophageal cancer patients not suitable for cisplatin
Authors
Bryan H. Burmeister
Euan T. Walpole
Elizabeth A. Burmeister
Janine Thomas
Damien B. Thomson
Jennifer A. Harvey
B. Mark Smithers
David C. Gotley
Publication date
01-08-2005
Publisher
Springer-Verlag
Published in
International Journal of Clinical Oncology / Issue 4/2005
Print ISSN: 1341-9625
Electronic ISSN: 1437-7772
DOI
https://doi.org/10.1007/s10147-005-0506-9

Other articles of this Issue 4/2005

International Journal of Clinical Oncology 4/2005 Go to the issue

ORIGINAL ARTICLE

Performance of outpatient regimen of S-1 in combination with fractional cisplatin for advanced or recurrent gastric cancers: a phase I study

REVIEW ARTICLE

Selective reconstructive options for the anterior skull base

CASE REPORT

Unknown primary carcinoma, diagnosed as inflammatory breast cancer,and successfully treated with trastuzumab and vinorelbine

INTRODUCTION TO REVIEW ARTICLES

Technical advances of plastic and reconstructive surgery in cancer surgery

ORIGINAL ARTICLE

Acute urinary morbidity following I-125 prostate brachytherapy

REVIEW ARTICLE

Functional reconstruction with free flaps following ablationof oropharyngeal cancer
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits